VolitionRx Ltd. Files Amended 10-K/A: Major Governance and Capital Structure Updates for Investors

Overview

VolitionRx Ltd. (NYSE American: VNRX), a diagnostics company specializing in epigenetics, has filed an Amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025. This amendment provides critical updates that were not included in the original filing, including details on directors, executive officers, governance, compensation, security ownership, and a significant capital structure change that could have immediate implications for shareholders and the company’s share value.

Key Highlights for Investors

• One-for-Twenty Reverse Stock Split Implemented
• Updated information on directors, executive officers, and governance committees
• Changes in insider and major shareholder ownership levels
• Updated executive and director compensation details
• Details on new and existing corporate governance and compliance policies

1. Reverse Stock Split: One-for-Twenty Affects Share Count and Price

In April 2026, following shareholder approval, VolitionRx effected a one-for-twenty reverse stock split of its common stock. The split took effect on April 28, 2026, with all trading, share, and per-share data retroactively adjusted. As a result, the number of outstanding shares of common stock has been significantly reduced, impacting all equity awards and share-based calculations in the report.

Shareholders need to note: After the reverse split, as of April 28, 2026, only 8,087,955 shares of common stock were issued and outstanding.

Market Value Impact: As of June 30, 2025, the aggregate market value of voting common stock held by non-affiliates was approximately \$72.9 million (based on the post-split price of \$15.20 per share). This calculation is based on the NYSE American closing price and may not reflect current market conditions.

This reverse split could be price-sensitive, as it directly affects per-share value, outstanding share counts, and could impact the liquidity and trading dynamics of VNRX shares.

2. Governance and Board Structure

Board and Committee Composition

• The company is led by President and CEO Cameron Reynolds, with Terig Hughes as Chief Financial Officer and Treasurer.
• VolitionRx has four key board committees:
  • Audit Committee: Responsible for oversight of financial reporting, auditor independence, internal controls, and cybersecurity. The committee is fully independent and includes Mr. Innes (Chair), Drs. Barnes, Colman, and Rubin. Mr. Innes is the designated “audit committee financial expert.”
  • Compensation Committee: Oversees executive and director pay, incentive plans, and compliance with clawback and forfeiture policies. Also reviews executive performance goals.
  • Nominations and Governance Committee: Manages board and committee nominations, succession planning, and ESG (Environmental, Social, Governance) practices. Evaluates potential director conflicts and supports sustainable growth initiatives.
• The company has adopted a Code of Ethics and insider trading policies applicable to all directors, officers, and employees. These are available on the investor relations section of the company’s website.

3. Executive and Director Compensation

The amended filing provides detailed breakdowns of compensation for the CEO and other executive officers, including salary, bonuses, stock awards, and other compensation.

• Cameron Reynolds (President & CEO) 2025 Compensation:
  • Salary: \$351,901
  • Bonus: \$31,721 (primarily tied to corporate goal achievement)
  • Stock Awards: \$638,233 (includes performance-based and deferred restricted stock units)
• Significant changes in accounting treatment for restricted stock units, now reflecting a recalculated amortization and fair value under ASC 718.
• Details on outstanding equity awards, including those subject to performance and market-based vesting conditions (e.g., awards that vest if the stock trades above \$50 for 30 consecutive trading days).
• Updated director compensation table, with fees and stock awards for non-executive directors clearly itemized.

Compensation structures that are heavily equity-based may align executives’ interests with shareholders but could be price-sensitive if large tranches vest or are exercised.

4. Insider and Major Shareholder Ownership

The amended report includes an updated ownership table (as of April 28, 2026, post-reverse split), showing the beneficial holdings of directors, officers, and major (>5%) shareholders.

• All directors and executive officers as a group (16 persons): 579,456 shares, or 7.1% of outstanding common stock.
• Largest shareholders include:
  • Eight Corporation Limited: 600,267 shares (7.4%)
  • Lagoda Investment Management, L.P. and affiliates
  • Lind Global Asset Management XII LLC: 2,234,025 shares (4.99%)
• Ownership calculations take into account options, warrants, and restricted stock units exercisable or vesting within 60 days.
• No director, officer, or affiliate is currently involved in any material legal proceedings adverse to the company.

Significant changes in insider or institutional holdings, especially in the context of a reverse split, could be interpreted by the market as positive or negative, depending on the direction and rationale.

5. Other Price-Sensitive Disclosures

• No Restatement or Correction of Prior Financials: The amendment does not reflect the correction of any prior errors or require any compensation clawback analysis.
• Not a Shell Company: The company affirms it is not a shell company and has been timely in its SEC filings.
• Insider Trading Policy: The company has adopted and filed an updated insider trading policy as an exhibit, which may be relevant to trading windows and blackout periods for insiders.

Conclusion: What Investors Should Watch

• The reverse stock split is the most critical and price-sensitive development. It reduces the number of outstanding shares, which may impact liquidity, institutional eligibility, and could make the stock more appealing to new investors by raising the per-share price.
• Updated governance and insider ownership levels provide transparency and may reassure investors about board oversight and alignment of interests.
• Executive compensation and equity awards could become a focus, especially if performance triggers are met and substantial stock-based awards vest.

Shareholders should closely monitor subsequent SEC filings for any further changes to governance, compensation, or insider transactions, especially in the wake of the reverse split.

Disclaimer: This article is a summary and analysis of VolitionRx Ltd.’s Amended Annual Report on Form 10-K/A for the year ended December 31, 2025. It is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should review the official SEC filings and consult with their financial advisors before making any investment decisions.

View VOLITIONRX LTD Historical chart here